Latest guidance given with Q1 FY2027 results, 29 Oct 2026
| Measure | Period | Guidance | As stated |
|---|---|---|---|
| EPS · Adjusted | FY2027 | $12.00 to $12.25 | Non-GAAP Diluted EPS $12.00 - $12.25 |
Source: the company's earnings release.
In its results release of 29 Oct 2026 (Q1 FY2027), ResMed| gave 1 forecast in figures, among them EPS (adjusted) of $12.00 to $12.25 for FY2027.
Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.
| Measure | Period | Guidance | As stated |
|---|---|---|---|
| EPS · Adjusted | FY2027 | $12.00 to $12.25 | Non-GAAP Diluted EPS $12.00 - $12.25 |
Source: the company's earnings release.
The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.
| Measure | Period | Last guidance | Revisions | Delivered | Result |
|---|---|---|---|---|---|
| EPS · Adjusted | FY2027 | $12.00 to $12.25 | Given once | — | To come |
Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.